Endocyte, Inc. (NASDAQ:ECYT)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $10.34, but opened at $10.38. Endocyte shares last traded at $10.41, with a volume of 2119823 shares.
A number of equities analysts recently weighed in on ECYT shares. BidaskClub raised shares of Endocyte from a “sell” rating to a “hold” rating in a research note on Saturday, March 3rd. ValuEngine raised shares of Endocyte from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. Zacks Investment Research raised shares of Endocyte from a “sell” rating to a “hold” rating in a research note on Friday, February 9th. Cowen raised shares of Endocyte from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 27th. Finally, Wells Fargo began coverage on shares of Endocyte in a research note on Friday, March 9th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Endocyte has an average rating of “Buy” and a consensus price target of $7.00.
The stock has a market cap of $683.07, a P/E ratio of -7.74 and a beta of 1.02.
Endocyte (NASDAQ:ECYT) last posted its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.02). Endocyte had a negative net margin of 78,662.86% and a negative return on equity of 40.33%. The company had revenue of $0.01 million during the quarter. During the same period in the prior year, the business posted ($0.26) earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. equities research analysts predict that Endocyte, Inc. will post -0.87 EPS for the current fiscal year.
In other Endocyte news, VP Christopher P. Leamon sold 5,036 shares of Endocyte stock in a transaction on Friday, March 9th. The shares were sold at an average price of $9.07, for a total value of $45,676.52. Following the completion of the sale, the vice president now directly owns 143,470 shares of the company’s stock, valued at $1,301,272.90. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Philip S. Low sold 50,511 shares of the business’s stock in a transaction dated Thursday, December 28th. The stock was sold at an average price of $4.41, for a total transaction of $222,753.51. Following the sale, the insider now directly owns 354,050 shares of the company’s stock, valued at $1,561,360.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 106,058 shares of company stock valued at $491,184. Insiders own 14.86% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Perceptive Advisors LLC bought a new stake in shares of Endocyte during the fourth quarter worth about $6,213,000. Goldman Sachs Group Inc. increased its position in shares of Endocyte by 1,443.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 173,759 shares of the biopharmaceutical company’s stock worth $744,000 after acquiring an additional 162,498 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Endocyte by 42.0% during the fourth quarter. Renaissance Technologies LLC now owns 293,580 shares of the biopharmaceutical company’s stock worth $1,257,000 after acquiring an additional 86,800 shares in the last quarter. AXA bought a new stake in shares of Endocyte during the fourth quarter worth about $101,000. Finally, Geode Capital Management LLC increased its position in shares of Endocyte by 15.6% during the fourth quarter. Geode Capital Management LLC now owns 241,498 shares of the biopharmaceutical company’s stock worth $1,033,000 after acquiring an additional 32,603 shares in the last quarter. 41.56% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Endocyte (ECYT) Shares Gap Down to $10.38” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/17/endocyte-ecyt-shares-gap-down-to-10-38.html.
Endocyte Company Profile
Endocyte Inc (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.